AusBiotech has today welcomed the appointment of industry nominee Michelle Burke to the Pharmaceutical Benefits Advisory Committee (PBAC), who is a highly-respected leader in the biotechnology and pharmaceutical sectors.
For more than 20 years Ms Burke has made substantial contributions in areas including access to medicines, industry development and the development of strong policy frameworks directed at improving patient health.
In the biotechnology sector, Ms Burke is a Director on the board of AusBiotech and was also a member of the Victorian Government’s Biotechnology Advisory Council until 2015.
Ms Burke has been the recipient of three peer-nominated awards from Medicines Australia in recognition of her contributions on policy reforms and has sat on the joint industry and government “Access to Medicines Working Group”.
The appointment of an industry nominated member to the PBAC has been welcomed by industry as an important consideration, providing a broader perspective on access to medicines and was one of several changes made to the Committee as part of the 2015 PBS Access and Sustainability Package.
“AusBiotech fully supports the appointment of Ms Burke, as an appointment of the highest integrity and standing, as well as significant experience in the regulation and reimbursement of medicines in Australia,” said Chair of AusBiotech, Ms Julie Phillips.
The PBAC is an independent expert body appointed by the Australian Government. Members include doctors, health professionals, health economists and consumer representatives.
-ENDS-
Media enquiries: Lorraine Chiroiu, AusBiotech’s Deputy CEO,
lchiroiu@ausbiotech.org / P: +61 (0) 3 9828 1414 /M: +61 (0) 429 801 118
About AusBiotech
AusBiotech is Australia’s biotechnology organisation, working on behalf of members for more than 30 years to provide representation and services to promote the global growth of Australian biotechnology. AusBiotech is a well-connected network of over 3,000 members in the life sciences, including therapeutics, medical technology (devices and diagnostics), food technology and agricultural, environmental and industrial sectors.
For more than 20 years Ms Burke has made substantial contributions in areas including access to medicines, industry development and the development of strong policy frameworks directed at improving patient health.
In the biotechnology sector, Ms Burke is a Director on the board of AusBiotech and was also a member of the Victorian Government’s Biotechnology Advisory Council until 2015.
Ms Burke has been the recipient of three peer-nominated awards from Medicines Australia in recognition of her contributions on policy reforms and has sat on the joint industry and government “Access to Medicines Working Group”.
The appointment of an industry nominated member to the PBAC has been welcomed by industry as an important consideration, providing a broader perspective on access to medicines and was one of several changes made to the Committee as part of the 2015 PBS Access and Sustainability Package.
“AusBiotech fully supports the appointment of Ms Burke, as an appointment of the highest integrity and standing, as well as significant experience in the regulation and reimbursement of medicines in Australia,” said Chair of AusBiotech, Ms Julie Phillips.
The PBAC is an independent expert body appointed by the Australian Government. Members include doctors, health professionals, health economists and consumer representatives.
-ENDS-
Media enquiries: Lorraine Chiroiu, AusBiotech’s Deputy CEO,
lchiroiu@ausbiotech.org / P: +61 (0) 3 9828 1414 /M: +61 (0) 429 801 118
About AusBiotech
AusBiotech is Australia’s biotechnology organisation, working on behalf of members for more than 30 years to provide representation and services to promote the global growth of Australian biotechnology. AusBiotech is a well-connected network of over 3,000 members in the life sciences, including therapeutics, medical technology (devices and diagnostics), food technology and agricultural, environmental and industrial sectors.
